Evidence map›Paper›PMID 39738967›Full record

SynthesisActa neurologica Belgica2025

Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis.

Ocílio Ribeiro Gonçalves, Arquimedes Barros Nascimento, Victor Gonçalves Soares, David Abraham, Gabriel de Almeida Monteiro, João Luís Reis Freitas, Jonatas Paulino da Cunha Monteiro Ribeiro, Bianca Leal Ribeiro, João Victor Araújo de Oliveira, Marco Antonnio Rocha Dos Santos and 3 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Acta neurologica Belgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ocílio Ribeiro GonçalvesFederal University of Piauí, Teresina, PI, Brazil.
Arquimedes Barros NascimentoFederal University of Piauí, Teresina, PI, Brazil.
Victor Gonçalves SoaresFederal University of Vales Do Jequitinhonha and Mucuri, Diamantina, MG, Brazil.
David AbrahamFederal University of Amazonas, Manaus, Amazonas, Brazil.
Gabriel de Almeida MonteiroDepartment of Neurosurgery, Federal University of Ceará, Sobral, CE, Brazil.
João Luís Reis FreitasUniversity of São Paulo (USP), São Paulo, Brazil.
Jonatas Paulino da Cunha Monteiro RibeiroFederal University of Piauí, Teresina, PI, Brazil.
Bianca Leal RibeiroFederal University of Piauí, Teresina, PI, Brazil.
João Victor Araújo de OliveiraFederal University of Piauí, Teresina, PI, Brazil.
Marco Antonnio Rocha Dos SantosUniversity of the Plateau of Santa Catarina, Lages, SC, Brazil.
João Paulo Mota TellesDepartment of Neurology, University of São Paulo (USP), São Paulo, Brazil.
Flávio Sekeff-SallemDepartment of Neurology, University of São Paulo (USP), São Paulo, Brazil.
Kelson James AlmeidaFederal University of Piauí, Teresina, PI, Brazil. kelson.almeida@ufpi.edu.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecent evidence indicates that statins have anti-inflammatory and antioxidant effects, leading to several investigations of whether statins have a neuroprotective effect and may benefit patients with Parkinson's disease (PD). However, the potential mechanisms of this class of medications as modifiers of the course of PD in already diagnosed patients is still unclear.

objectivesTo assess the effectiveness of statins as modifiers of established PD.

methodsTwo investigators systematically searched for randomized clinical trials and observational studies comparing PD patients treated with statins versus those treated without statins. The search was conducted in PubMed, Embase, Cochrane, and Web of Science. The outcome of interest was the change in the MDS-UPDRS III (Movement Disorder society-Unified Parkinson's Disease Rating Scale Part III) and UPDRS III scores from baseline. Statistical analysis was performed using R Studio 4.3.2.

resultsFour studies, totaling 472 patients, were included. The standardized mean difference for the MDS-UPDRS Part III and UPDRS Part III scales between statin and non-statin groups was - 0.13 (95% CI - 0.44 to 0.17; p = 0.39; I

conclusionThere was no statistical significance for the potential clinical benefit of statins as modifiers of the disease course in PD patients.

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsParkinson DiseaseHumansObservational Studies as TopicRandomized Controlled Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsMeta-AnalysisNeurodegenerationNeurologyParkinson’s DiseaseStatins

Identifiers

PMID39738967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.